![](https://endpts.com/wp-content/uploads/2022/07/Gilmore-ONeill-Editas.jpg)
Gilmore O’Neill, Editas Medicine CEO
Editas halts lead CRISPR program after efficacy data underwhelm
Editas Medicine will put a wrap on its lead clinical program after reporting disappointing results from a Phase I/II trial.
The biotech, one of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.